What methods are currently available to prevent and treat antibiotic-associated diarrhoea in children?

Unwanted drug reactions of the gastrointestinal tract (GIT), often with the development of antibiotic-associated diarrhoea (AAD), are the most frequent adverse effects of antibacterial therapy in outpatient practice. This review presents the most current data on antibiotic-associated intestinal lesions. It provides up-to-date information on the epidemiology and etiology of microbial factors of AAD and pseudomembranous colitis.

The authors cite clinical forms of AAD, which range from idiopathic with a picture of enteritis to pathogen-specific AAD (antibiotic-associated colitis). A comprehensive approach to AAD verification and patient management tactics makes it possible to significantly reduce the number and severity of possible complications. AAD, including C. difficile-associated diarrhoea/colitis, should be suspected in any patient with diarrhoea who has received antibiotics in the previous 2 months. In addition to clinical signs, laboratory tests confirming clostridial infection should be evaluated. The article presents the algorithm of the comprehensive approach to the treatment of antibiotic-associated diarrhea (AAD), which along with the use of metronidazole and vancomycin places a high priority on the probiotics, which not only prevents relapse, but also protects from this pathology.

The article presents general characteristics of probiotic preparations, mechanisms of action of probiotics: antagonistic influence on pathogenic and opportunistic bacteria of microbiota, strengthening of mucous barrier of gastrointestinal tract, and also influence on modulation of immune response, as a result of which the chain of mechanisms of immunological protection starts. On the basis of publications of domestic and foreign researchers, the possibilities of using various probiotic strains of bacteria, and in particular, the prospects of using Lactobacillus reuteri, have been considered.

1. Versporten A., Bolokhovets G., Ghazaryan L., et aL. Antibiotic use in eastern Europe: a crossnational database study in coordination with the WHO Regional Office for Europe. Lancet Infect Dis. 2014;14(5):381-387. doi: 10.1016/S1473-3099(14)70071-4.

2. Giannelli F.R. Antibiotic-associated diarrhea. JAAPA. 2017;30(10):46-47. doi: 10.1097/01.JAA.0000524721.01579.c9.

3. McFarland L.V. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis. 1998;16(5):292-307. doi: 10.1159/000016879.

4. Owens R.C. Jr., Ambrose P.G. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41(Suppl. 2):144-157. doi: 10.1086/428055.

5. Salvo F., De Sarro A., Caputi A.P., Polimeni G. Amoxicillin and amoxicillin plus clavulanate: a safety review. Expert Opin Drug Saf. 2009;8(1):111-118. doi: 10.1517/14740330802527984.

6. Hogenauer C., Hammer H.F., Krejs GJ., Reisinger E.C. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis. 1998;27(4):702-710. doi: 10.1086/514958.

7. Bartlett J.G. Antibiotic-associated diarrhea. Clin Infect Dis. 1992;(15):573-581. doi: 10.1093/clind/15.4.573.

8. Zakharenko S.M., Andreeva I.V., Stetsiouk O.U. Gastrointestinal adverse drug reactions and antibiotic-associated diarrhea during antibiotic therapy in outpatient practice: prevention and treatment. Klinicheskaya mikrobiologiya i Antimikrobnaya Khimioterapiya = Clinical Microbiology and Antimicrobial Chemotherapy 2019;21(3):196-206. (In Russ). Available at: https://cmac-journal.ru/publication/2019/3/cmac-2019-t21-n3-p196/cmac-2019-t21-n3-p196.pdf.

9. Wermeille J., Cunningham M., Dederding J.P., Girard L., Baumann R., Zelger G., et al. Failure of Helicobacter pylori eradication: is poor compliance the main cause? Gastroenterol Clin Biol. 2002;26(3):216-219. Available at: https://www.em-consulte.com/en/article/159007.

10. Sanches B., Coelho L., Moretzsohn L., Vieira G. Jr. Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options. Helicobacter. 2008;13(6):572-576. doi: 10.1111/j.1523-5378.2008.00649.x.

11. Mitchell D.K., Van R., Mason E.H., Norris D.M., Pickering L.K. Prospective study of toxigenic Clostridium difficile in children given amoxicil-lin/clavulanate for otitis media. Pediatr Infect Dis J. 1996;15(6):514-519. doi: 10.1097/00006454-199606000-00008.

12. Vanderhoof J.A., Whitney D.B., Antonson D.L., Hanner T.L., Lupo J.V., Young RJ. Lactobacillus GG in the prevention of antibioticassociated diarrhea in children. J Pediatr. 1999;135(5):564-568. doi: 10.1016/S0022-3476(99)70053-3.

13. Arvola T., Laiho K., Torkkeli S., Mykkanen H., Salminen S., Maunula L., et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics. 1999;104(5):e64. doi: 10.1542/peds.104.5.e64.

14. Turck D., Bernet J.P., Marx J., Kempf H., Giard P., Walbaum O., et al. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr. 2003;37(1):22-26. doi: 10.1097/00005176-200307000-00004.

15. La Rosa M., Bottaro G., Gulino N., Gambuzza F., Di Forti F., Ini G., et al. Prevention of antibiotic-associated diarrhea with Lactobacillus sporo-gens and fructo-oligosaccharides in children. A multicentric double-blind vs placebo study. Minerva Pediatr. 2003;55(5):447-452. Available at: http://europepmc.org/article/med/14608267.

16. Seki H., Shiohara M., Matsumura T., Miyagawa N., Tanaka M., Komiyama A., et al. Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr Int. 2003;45(1):86-90. doi: 10.1046/j.1442-200X.2003.01671.x.

17. Kotowska M., Albrecht P., Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2005;21(5):583-590. doi: 10.1111/j.1365-2036.2005.02356.x.

18. Damrongmanee A., Ukarapol N. Incidence of antibioticassociated diarrhea in a pediatric ambulatory care setting. J Med Assoc Thai. 2007;90(3):513-517. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17427529.

19. Ruszczynski M., Radzikowski A., Szajewska H. Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Aliment Pharmacol Ther. 2008;28(1):154-561. doi: 10.1111/j.1365-2036.2008.03714.x.

20. Bargozzi E., Gaiazzi M., Meneghin F., Ramponi G., Zuccotti G., Cardile S., et al. Antibiotic associated diarrhea in children: What happens in real life? Digestive and Liver Disease. 2013;(45):263-311. doi: 10.1016/j.dld.2013.08.150.

21. Kanner E.V., Gorelov A.V., Krutikhina S.B. Antibiotic-associated diarrhea in children: a current view of the problem. Meditsinskiy sovet = Medical Council. 2017;(1):226-230. (In Russ.) doi: 10.21518/2079-701X-2017-1-226-230.

22. Baryshnikova N., Belousova L. Antibiotics and probiotics: provision of efficacy and safety. Vrach = The Doctor. 2012;(1):26-28. (In Russ.) Available at: http://gyn.rusvrach.ru/archive/vrach-2012-01-07.pdf.

23. Tkachenko E.I., Uspenskiy YU.P. Pitaniye, mikro-biotsenoz i intellekt cheloveka = Nutrition, microbiocenosis and human intelligence. SPb.: SpetsLit; 2006. 590 p. (In Russ.) Available at: https://ru.b-ok.cc/book/2901559/30f758.

24. Suvorov A.N., Tkachenko E.I., Uspenskiy YU.P. (ed.). Disbioz kishechnika. Rukovodstvo po diag-nostike i lecheniyu = Intestinal disbiosis. Diagnostic and Treatment Guide. 3rd ed., corrected and supplemented. St. Petersburg: InformMed; 2013. 270 p. (In Russ.)

25. Hickson M. Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Ther Adv Gastroenterol. 2011;4(3):185-197. doi: 10.1177/1756283X11399115.

26. Uspenskiy YU., Baryshnikova N. Intestinal disbi-osis and antibiotic-associated diarrhea in hospital conditions: prevention and correction. Vrach = The Doctor. 2019;30(12):81-85. (In Russ.) doi: 10.29296/25877305-2019-12-21.

27. Avadhani A., Miley H. Probiotics for prevention of antibiotic-associated diarrhea and Clostridium difficile-associated disease in hospitalized adults-a metaanalysis. J Am Acad Nurse. Pract. 2011;23(6):269-274. doi: 10.1111/j.1745-7599.2011.00617.x.

28. Videlock E., Cremonini F. Meta-analysis: probiotics in antibiotic-associated diarrhea. Aliment Pharmacol Ther. 2012;35(12):1355-1369. doi: 10.1111/j.1365-2036.2012.05104.x.

29. Bordin D.S., Indeykina L.KH., Voynovan I.N., Sabel'nikova E.A. Antibiotic-associated diarrhoea and eradication Helicobacter pylori: ways to prevent. Ehffektivnaya farmakoterapiya. Gastroehnterologiya. = Effective Pharmacotherapy. Gastroenterology. 2019;15(28):52-57. (In Russ.) doi: 10.33978/2307-3586-2019-15-28-52-57.

30. Khavkin A.I. Antibiotic-Associated Diarrhea: The Possibilities of Using Probiotics. Trudnyy pat-sient = Difficult Patient. 2018;(1-2):48-52. (In Russ.) Available at: http://t-pacient.ru/wp-con-tent/uploads/2018/03/11.pdf.

31. Surawicz C.M., Brandt L.J., Binion D.G., Ananthakrishnan A.N., et al. Guidelines for diagnosis, treatment and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478-498. doi: 10.1038/ajg.2013.4.

32. Ivashkin V.T., Yushchuk N.D., Mayev I.V., Lapina T.L., Poluektova Y.A., Shifrin O.S., Tertychny A.S., Trukhmanov A.S., Sheptulin A.A., Baranskaya Y.K., Lyashenko O.S., Ivashkin K.V. Diagnostics and treatment of Clostridium difficile-associated disease: Guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(5):56-65. (In Russ.) doi: 10.22416/1382-4376-2016-26-5-56-65.

33. Szajewska H., Canani R.B., Guarino A., Hojsak I., et al; ESPGHAN Working Group for ProbioticsPrebiotics. Probiotics for the prevention of antibiotic-associated diarrhea in children. J Pediatr Gastroenterol Nutr. 2016;62(3):495-506. doi: 10.1097/MPG.0000000000001081.

34. Shelygin YU.A., Aleshkin V.A., Sukhina M.A. et al. Clinical recommendations of the National Association of specialists in the control of infections associated with medical care and the AllRussian Public Non-Profit Organization “Association of Coloproctologists of Russia“ on diagnosis, treatment and prevention of clostridium difficile-associated diarrhea (CDI). Moscow; 2017. 24 p. (In Russ.) Available at: http://www.gnck.ru/rec/recommendation_clostridium_diffi-cile.pdf.

35. D'Souza A.L., Rajkumar C., Cooke J., Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ. 2002;324(7350):1361. doi: 10.1136/bmj.324.7350.1361.

36. Sansotta N., Peroni D.G., Romano S., et al. The good bugs: the use of probiotics in pediatrics. Curr Opin Pediatr. 2019;31(5):661-669. doi: 10.1097/MOP.0000000000000808.

37. Egan K., Field D., Rea M.C., Ross R.P., Hill C., Cotter P.D. Bacteriocins: Novel Solutions to Age Old Spore-Related Problems? Front Microbiol. 2016;8(7):461. doi: 10.3389/fmicb.2016.00461

38. Reid G., Burton J. Use of Lactobacillus to prevent infection by pathogenic bacteria. Microbes Infect. 2002;(4):319-324. doi: 10.1016/s1286-4579(02)01544-7.

39. Cherian P.T., Wu X., Yang L., Scarborough J.S., Singh A.P., Alam Z.A., Lee R.E., Hurdle J.G. Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection. J Antimicrob Chemother. 2015;70(11):3061-3069. doi: 10.1093/jac/dkv231.

40. Abhisingha M., Dumnil J., Pitaksutheepong C. Selection of potential probiotic Lactobacillus with inhibitory activity against Salmonella and fecal coliform bacteria. Probiotics Antimicrob Proteins. 2018;10(2):218-227. doi: 10.1007/s12602-017-9304-8.

41. Srinivasan R., Kesavelu D., Veligandla K.C., Muni S.K., Mehta S.C. Lactobacillus reuteri DSM 17938: Review of Evidence in Functional Gastrointestinal Disorders. Pediatr Ther. 2018;8(3):350. doi: https://doi. org/10.4172/2161-0665.1000350.